Seeking Alpha

Insmed Inc. (INSM)

()

News & PR
Market Currents

Buzz
Twitter: INSM

Business Intelligence
Transcripts
Events
Key Developments

Instablog posts on INSM

Value Stock Screen: Potential Activist Targets by The Manual of Ideas
Top activist investors typically look for companies that can unlock significant shareholder value through a specific corporate event, such as a sale, liquidation or recapitalization.Activists scour the investment landscape for companies that are not controlled, i.e., firms in which senior... More »
July 25, 2009 • TRID, FACT, QLTI
INSMED’S (INSM) DRUG IPLEX™: VALUABLE, OR NOT VALUABLE? by Prohost Biotech
After Insmed announced results from phase 2 clinical trial evaluating Iplex™ (mecaser-min rinfabate) on patients with myotonic muscular dystrophy ("MMD"), investors instigated a hysterical sell off of INSM on a very high volume. Capital is a coward, we know, especially in shaky... More »
July 13, 2009 • INSM
Big lineup of healthcare stocks crack Russell 3000® Index by M. E. Garza
It’s official, the new list of Russell 3000® stocks has been unveiled and a big lineup of healthcare sector companies who were looking to bring value to their shareholders and expose their stocks to a broader base of institutional investors have succeeded.Certainly, speaking to the... More »
June 30, 2009 • AHCI, ALLI, ANCI
FDA Calendar Updates: AZN, BMY, OSUR, CPD, INSM, H. Lundbeck by Mike Havrilla
Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch... More »
June 25, 2009 • HLUKY.PK, CPD, INSM
Healthcare Market Movers - SMMX, INSM, ADLS, HEB, ACUR and HALO by M. E. Garza
Rumors, takeovers and accusations moved stocks in the market's healthcare sector as foreign investors continue to show a healthy appetite for U.S. debt. The day's flat performance followed the worst single-day decline for stocks in two months. Laboratory Corporation of America (NYSE: LH) said on... More »
June 24, 2009 • SMMX, INSM, ADLS
BioMedReports FDA Calendar: Hot Summer Trades by Mike Havrilla
Below is a sample of entries from the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The companies outlined below have expected FDA new drug product decisions or clinical trial results expected over the next three months of summer. The list also includes some... More »
June 15, 2009 • RIGL, AEZS, INSM
10 Extreme Trades on Pending Clinical Trial Results by Mike Havrilla
As a follow-up to my recent article on nine extreme FDA trades of pending new product decisions among small and micro-cap companies, I have examined the BioMedReports.com Clinical Trial Calendar database to find companies with market caps below $250M which have pending Phase 2 or 3 clinical... More »
May 13, 2009 • GNTA, RMTI, PARD
FDA, Clinical Trial Calendar Updates: Insmed, Jazz Pharma Await Key Results by Mike Havrilla
Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision... More »
May 13, 2009 • JAZZ, MRK, INSM

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Insmed Inc. (INSM)

Instablog posts on INSM

Value Stock Screen: Potential Activist Targets by The Manual of Ideas

INSMED’S (INSM) DRUG IPLEX™: VALUABLE, OR NOT VALUABLE? by Prohost Biotech

Big lineup of healthcare stocks crack Russell 3000® Index by M. E. Garza

FDA Calendar Updates: AZN, BMY, OSUR, CPD, INSM, H. Lundbeck by Mike Havrilla

Healthcare Market Movers - SMMX, INSM, ADLS, HEB, ACUR and HALO by M. E. Garza

BioMedReports FDA Calendar: Hot Summer Trades by Mike Havrilla

10 Extreme Trades on Pending Clinical Trial Results by Mike Havrilla

FDA, Clinical Trial Calendar Updates: Insmed, Jazz Pharma Await Key Results by Mike Havrilla

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers